NEK2 and cancer: Although CMP3a represented a unique mode of action for sensitizing GSCs with elevated Nek2 levels and presented a promising option for future cancer therapies, it did not have a favorable pharmacokinetic profile (a short half-life), and thus failed to advance in clinical trials.